Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment
- PMID: 1145932
- DOI: 10.1016/0090-4295(75)90704-9
Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment
Abstract
Twenty-six patients with advanced prostatic carcinoma refractory to conventional endocrine treatment were treated with a new oral nonsteriodal antiandrogen, flutamide. There were 6 responders and 20 failures. No serious toxicity attributable to flutamide was observed.